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Abstract 
Health care in Bhutan is free and the Essential Drugs Program 
under the Ministry of Health has been able to provide high quality 
effective medicines for the people. The bulk of these medicines is 
imported from generic companies in India, where based on its 
1970 patent laws, copies of patented drugs were manufactured 
using different processes which made it cheap and affordable for 
many developing countries. However with the enactment in India 
of its new patent laws in 2005 and with Bhutan becoming a 
member of the WTO, the affordability of those medicines developed 
post-1995 will become severely limited. With both India and 
Bhutan becoming TRIPS compliant, we will have to incorporate 
and amend our national laws and review how best we can utilize 
the flexibilities in TRIPS, afforded by the Doha Declaration and the 
Decision of the General Council. We need to address these issues 
if we are to safeguard public health and to continue to access 
affordable high quality medicines for our people. 
Introduction 
With the small population of approximately 700,000, Bhutan 
has made significant strides in health since 1961, when the 
health department and the first hospital were established.1 
Health care is free for all citizens, delivered through public 
hospitals and dispensaries. Access to health care is good with 
90 % of the population having access to a health center 
within 3 hours walking distance.2 The Drugs, Vaccines and 
Equipments division (DVED) is responsible for the purchase 
and supply of all medicine, throughout the country.  
                                              
∗ Pediatrician, JDWNR Hospital, Thimphu. 
1 Planning Commission (1999). Bhutan 2020. A vision for peace, 
prosperity and happiness., Thimphu: Royal Government of Bhutan. 
2 Department of Health Services (2000). A Report: National Health 
Survey 2000, Thimphu: Royal government of Bhutan. 
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In the 9th five year plan (2002-06) the ministry of health 
received 6.4 % of the total budget outlay, which is one of the 
highest in the region.3 Like most developing countries 
procurement of pharmaceuticals accounted for the second 
highest expenditure.4 The Essential Drug Program (EDP), 
which began in 1987, distributes medicines to different levels 
of care and is considered exemplary by the World Health 
Organization (WHO).5 It noted that 90 % of people had access 
to high quality essential drugs, and only 0.75 % of the overall 
budget was wasted on expiry drugs. The National Drug Policy 
guides the procurement and supply of medicines usually from 
pre-qualified suppliers and through central procurement. The 
government was thus able to negotiate and purchase these 
essential medicines at a price that was 50% below the world 
market prices.6  
 
Regular prescription and drug utilization surveys enable 
pharmacists to interact closely with doctors and ensure that 
the medicines are put to their best use with minimum waste. 
The people thus benefit from these policies, with access to 
health care made available by the government and the EDP 
ensuring timely availability of high quality drugs. However 
with Bhutan on the verge of becoming a member of the World 
Trade Organization (WTO), we will have to comply with the 
TRIPS (Trade related aspects of intellectual property rights) 
agreement and this poses several challenges to accessing and 
being able to afford essential medicines. To aggravate the 
situation, India who is our biggest source of essential drugs, 
enacted its new patent laws and like other least developed 
countries (LDC), Bhutan will find it difficult to maintain the 
present system of providing free, cheap, high quality 
                                              
3 National Statistical Bureau (2004). Statistical Yearbook of Bhutan, 
2003, Thimphu: Royal Government of Bhutan. 
4 Hogerzeil, H.V. (2005). “The concept of essential medicines: lessons 
for rich countries,” British Medical Journal, 329. 
5 Organization WH. Bhutan: Health infrastructure. In; 2002. Available 
at http://w3.whosea.org/ehp/pdf/books/bhu-2003/resources.pdf 
6 Group TFW (2004). Millennium project: Access to Essential 
medicines, Geneva: United Nations Development Fund (UNDP). 




There have been several discussions from various sectors on 
the advantages and disadvantages of becoming a member of 
the WTO here in Bhutan, however very little has been 
discussed or written from the health perspective. This paper 
will therefore discuss the issue of access and affordability of 
medicines in relationship to TRIPS, which is the major 
consequence for health on Bhutan becoming a member of the 
WTO.  
Background to TRIPS and its challenges to developing countries 
In 1994, when the WTO was formed, its member states 
adopted TRIPS as a means for securing intellectual property 
protection for pharmaceuticals and other technologies. The 
reason for this was to encourage funding and to provide 
incentives for big pharmaceutical companies to continue to 
research and develop new drugs. It costs between US $402-
793 million,7 and takes 10-15 years of research to put new 
medicines into the market. TRIPS enabled these major R&D 
pharmaceutical companies to recover their costs by way of 
patents. As per article 27 of the TRIPS agreement, patents on 
these new drugs provided exclusive rights to the producer 
and prevented others from “making, using, offering for sale, 
selling or importing” the new product for a period of 20 years, 
during which time they not only regained their cost but also 
made huge profits. Developing countries were given until 
2000 to comply with TRIPS provisions and LDC’s were given 
six additional years until 2006, which was subsequently 
extended to 2016 with respect to medicines.  
 
Although theoretically this seems fair, in reality this puts 
developing countries at a huge disadvantage. 
 
Drug companies are driven by profits and therefore tend to 
                                              
7 DiMasi, J.A., Hansen, R.W. and Grabowski, H.G. (2003). “The price 
of innovation: new estimates of drug development costs,” J Health 
Econ, 22:151-185. 
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invest in developing medicines for diseases that are more 
prevalent in Western countries, mostly addressing the so 
called lifestyle diseases as these richer and bigger markets 
helped generate better profits. Diseases that are rampant in 
developing countries are neglected and it is for this reason 
that we have not seen any new drugs for diseases like 
tuberculosis, leishmaniasis, shigellosis and meningitis for the 
last three or four decades. Between 1975-1997 there were 
1,223 new chemical entities commercialized, out of which 379 
(30.9 %) were considered as therapeutic innovations and only 
13 were specific for tropical diseases and sadly only 4 were 
produced as a direct result of R & D conducted by 
pharmaceutical industries.8 Even when new drugs are 
developed (e.g. artemesinin for malaria), they are too 
expensive to be affordable for a vast majority of people that 
need them.  
 
Developing countries on the other hand lack technical, 
financial and human resources to carry out research and 
develop new drugs, especially given that they must follow 
‘Good manufacturing practices’. This is a process by which 
new drugs have to pass through various stages to ensure that 
it is effective, safe and of high quality before the drug is 
marketed. All these requirements lead to high production 
costs, thereby making patented drugs expensive and out of 
reach for the poorer section of the world.  
 
Up until 2005, India had followed its own patent laws 
established in 1970, which granted patents to processes only 
and not for products. Therefore by using different processes 
such as reverse engineering, India was able to produce 
generic versions of patented medicines and this lead to the 
growth of a huge generic industry, which supplies 70% of the 
world’s generic medicines. In addition, for registration of 
these generics and to prove that the drug was bio-equivalent 
                                              
8 Pecoul, B, Chirac, B, Trouller, P et al. “Access to essential drugs in 
poor countries: a lost battle?” JAMA. Available at: 
http://www.accessmed-msf.org/prod/publication.asp 
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(of the same standard in terms of efficacy and quality) to the 
original patented drug, it did not have to pass through the 
same stringent process of testing and providing supportive 
data. It could use the evidence of the data submitted by the 
original company or proof of the original drugs registration by 
a stringent regulatory authority in another country. It also 
had the freedom to combine multiple patented drugs into a 
single tablet/capsule (there are no patents on fixed dose 
combinations) thereby making it convenient for the patients 
in terms of compliance. Since these drastically reduced the 
costs of production, generic medicines were much cheaper, 
leading to a major reduction in drug prices. The effects of 
these price differences were significantly seen with anti-
retroviral medicines, which are used for treating HIV/AIDS 
patients. With the pandemic reversing the development 
achievements in many African nations and threatening to do 
the same in Asia, a reduction in prices of anti-HIV/AIDS 
drugs from an unaffordable US $ 10,000 (for treating one 
patient for a year) to an affordable US $ 140 was a boon and 
a blessing for many developing countries combating this 
disease.  
 
While the countries of the south, non-governmental 
organizations (NGO’s), civil society and international 
humanitarian organizations welcomed this, the major drug 
companies were fuming, seeing their potential profits dwindle.  
They continued to exercise their influence with the support of 
their governments and pushed the WTO for more stringent 
measures to follow TRIPS protocol and on several occasions 
brought governments to the WTO for arbitration, which often 
ended in embarrassment for these companies.9 At the same 
time, developing countries continued to fight for more 
recognition of public health concerns and better access to 
cheap, effective and high quality generic drugs. This conflict 
came to the forefront in November 2001 at Doha, Qatar, 
which was regarded by many as a victory for developing 
                                              
9 Brazil, Abbot, & AIDS drugs patents. Available at: 
http://www.natap.org/2005/HIV/070805_01.htm 




The Doha Declaration of 2001 ensured access to cheap high 
quality generic drugs for diseases such as HIV, malaria and 
tuberculosis. It allowed countries such as India, Brazil and 
Thailand to use certain flexibilities within TRIPS, especially 
compulsory licenses, to continue to manufacture these 
essential drugs in the generic form.10 Article 31 (f) of TRIPS 
however, stated that compulsory licenses for the manufacture 
of medicines were to be issued “predominantly for the supply 
of the domestic market of the member”.11 Non-Producing 
Countries (NPC), like Bhutan, with no domestic 
pharmaceutical industry or market, cannot make use of 
compulsory licenses, and importing cheap generic drugs from 
India is the only lifeline. The only relevant comment for such 
countries from the declaration, is the instruction given to the 
“Council for TRIPS to find an expeditious solution to this 
problem” by 2002. Subsequently after nearly 2 years of 
debate in 2003, the General Council by way of its 30th 
August decision12 agreed to waive article 31 (f) of the TRIPS 
agreement for LDC’s and this was further supplemented with 
a statement by the General council chairman in 2003. 
Although several concessions were made and many of the 
points clarified, it made implementation of the flexibilities 
                                              
10 World Trade Organization (2001). Declaration on TRIPS agreement 
and public health. Ministerial declaration. Ministerial Conference, 




11 World Trade Organization. Agreement on Trade related aspects of 
intellectual property rights. Part II, Standards concerning the 
availability, scope and use of Intellectual property rights, Article 31 
(f).Available at: 
http://www.wto.org/english/tratop_e/trips_e/t_agm3c_e.htm. 
12 WT/L/540 and Corr.1. Decision of the General Council of 30 
August 2003. Implementation of paragraph 6 of the Doha 
Declaration on the TRIPS Agreement and public health. Available at: 
http://www.wto.org/English/tratop_e/trips_e/implem_para6_e.htm 
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cumbersome and impractical.13 Countries intending to import 
or export medicines had to pursue several labyrinthine 
procedures and fulfil all the criteria as set out by the council 
making it unlikely for any member to use it effectively. Even if 
Bhutan attempts to meet the requirements mentioned in the 
decision, it is unlikely that the Indian companies willing to 
export drugs will take the initiative or the effort to fulfil their 
part of the criteria because of the myriad of labyrinthine 
procedures and the relatively small demand.14  
 
India’s decision to become TRIPS compliant with the passing 
of the Indian patent act by parliament in March 2005 will 
further aggravate the situation. Amidst a walkout by the 
opposition party, the controversial law was passed, and what 
was disheartening for most developing countries was that the 
law went beyond what was required by TRIPS.15 Under the 
new law, besides new chemicals and products, patents can 
also be given for formulations, new drug delivery systems and 
combinations, making it possible for companies to acquire 
patents on new uses of old drugs and on new combination of 
old drugs. This will severely restrict access to 
pharmaceuticals, even for those drugs that were made prior 
to 1995, which are exempt from patent laws. The new laws 
also make the exporting of compulsory licensed drugs illegal if 
the importing country does not have a license too. For 
Bhutan, which does not have to comply with TRIPS until 
2016, and where there are no patents for any drugs, it seems 
absurd to issue a compulsory license for a non-existent 
patent. With limited financial resources and heavily 
                                              
13 Correa, C.M. (2004). Implementation of the WTO General Council 
decision on paragraph 6 of the DOHA declaration on TRIPS 
agreement and public health. Department of Essential drugs and 
medicine policy, Geneva: World Health Organization. 
14 For example the number of HIV infected people is only 72 and 
there are a few hundred with tuberculosis and malaria. (Annual 
health bulletin 2003. Ministry of health, Royal government of 
Bhutan) 
15 Sharma, D.C. (2005). “Indian patents may hamper access to anti 
retroviral globally,” The Lancet, 5: 136 
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dependent on donors, Bhutan will not be able to afford the 
more expensive patented drugs. This can have serious impact 
on the sustainability of the present provision of free 
medicines. 
Effect of TRIPS on pricing, affordability and access 
Given its geographical location and rapid globalization, 
Bhutan reluctantly began its accession to the WTO in 2004, 
aware of the many pitfalls and the heavy disadvantages that it 
faced.16 However, very little discussion took place with 
regards to TRIPS and public health, and especially with 
affordability and accessibility of drugs. The application of 
national laws can still assist poor countries in accessing 
affordable drugs, however with limited trained professionals 
in all sectors we are yet to address such issues and to amend 
and refine our trade laws, in particular those related to 
TRIPS. Even after establishing relevant laws, it will be 
essential to have a system in place and a common 
understanding between all sectors in safeguarding our rights 
to use the flexibilities because companies can still find ways 
to block the export of drugs, as was seen in Philippines, 
where after issuing compulsory license for 51 drugs, only 1 
managed to be distributed and that too after 10 years of 
effort.17 
 
Bhutan also depends upon bilateral agencies and the UN for 
much of our revenue. For example, in 2000, 27.5% of our 
expenditure for public health came from external sources.18 
Even though we spend a high percentage of our budget on 
health, it will be difficult to sustain the delivery of free 
                                              
16 Wangyel, Tashi (2004). “Rhetoric and reality: An assessment of the 
possible impact of WTO on Bhutan,” in The Spider and the Piglet, 
Thimphu: The Center of Bhutan studies. 
17 Correa, C.M. (2004). Implementation of the WTO General Council 
decision on paragraph 6 of the DOHA declaration on TRIPS 
agreement and public health. Department of Essential drugs and 
medicine policy, Geneva: World Health Organization. 
18 World Health Organization. Health resources: Bhutan. Available at 
http://w3.whosea.org/cntryhealth/bhutan/bhuresource.htm.  
Journal of Bhutan Studies 
 136
medicines and continue our policy of free health care. 
Insurance companies are unlikely to take over the financing 
of health care because the numbers of clients are likely to be 
small and because of the absence of private hospitals and 
medical facilities in Bhutan. Moreover, more and more 
patients, those who can afford to pay the premiums will seek 
care in third countries making such ventures for insurance 
companies non-viable. Therefore, unless alternatives are 
explored and tested, Bhutan will not be able to afford the 
patented drugs with the present budget. 
 
Although health services will be accessible, the provision of 
free drugs may not be possible unless some mechanism of 
charging fees is developed. This will then lead to essential 
drugs becoming inaccessible to a majority of the population. 
Because poor people tend to pay out of pocket for medicines, 
there is a danger of having a 2-tier system of access, one 
having access to effective expensive drugs and the other to 
older, less effective, patent expired generics.19 
Options for utilizing the TRIPS flexibilities 
We are not required to be TRIPS compliant till 2016; however, 
since we do not have a domestic pharmaceutical industry, we 
are dependent on other countries, predominantly India, which 
has not only become TRIPS compliant but has also 
implemented its national laws incorporating these changes. It 
is for this reason that we need to address TRIPS and other 
issues in relation to public health so that we continue to 
safeguard the health of our people and ensure access to 
affordable and effective medicines. As a LDC/NPC, Bhutan is 
eligible to utilize the Para 6 Decision as an importer and to 
purchase generic medicines from any manufacturer. The only 
requirement as per the General Council August decision is for 
us to make a notification to the WTO in this regard. However 
for the exporter there are several procedures; seek voluntary 
license from the patent holder on commercially reasonable 
                                              
19 Mudur, G. (2005). “Changes to India’s patent law may deny cheap 
drugs to millions,” British Medical journal, 330: 692. 
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terms for a reasonable period, seek and obtain a compulsory 
license from its government, manufacture and export only the 
specified amount, pay royalties to the patent holder based on 
the commercial value in the importing country, investigate 
the patent holders product in the importing country and 
differentiate it significantly and prominently, seek registration 
and prove bio-equivalence to the regulatory authority in the 
importing country, and notify to the WTO along with postings 
of the entire detail on its website. This same procedure has to 
be replicated for every individual drug and for every country 
to which the exporter intends to export! Given these 
procedures, the consequent delay in production, and the cost 
implication, no generic manufacturer would be inclined to 
take the initiative, especially when you consider the small 
demand of the Bhutanese market.  
 
For Bhutan, the options available from the TRIPS flexibilities 
are to import no-patent drugs (older) without restriction or to 
negotiate with exporting countries for issuing of compulsory 
license for export. There are no restrictions on importing 
medicines from a no-patent country, but where there are 
patents, such as in India, we can import either only non-
predominant amounts or an unlimited amount depending 
upon whether a ordinary compulsory licence (Article 31 (f)) or 
a compulsory license to effect Article 31 (k) (related to patent 
abuse) is issued in the exporting country. Both of these are 
unlikely because of the limited commercial benefits for the 
drug manufacturer, an incapacity to reach economies of 
scale, and its adverse impact on foreign direct investment.  
 
Another option to consider is to seek and negotiate with the 
exporting country for an Article 30 Limited exception export, 
whereby it permits a pharmaceutical company to 
manufacture products for export to a no-patent country or in 
response to a compulsory license from a NPC. This is 
considered by many, including international organisations 
like the World Health Organisation, to be the most efficient 
and expeditious way to access cheaper generic medicines. 
However, there is very limited experience in using this clause 
Journal of Bhutan Studies 
 138
and it therefore may be considered risky by the 
manufacturer. It will also require strong legislative authority 
and the support of the government. Developed countries and 
the patent holder can still challenge this limited exception 
rule and bring the case before the WTO.  But given the 
commercial risk, many exporters will not have enthusiasm for 
this route.  
 
Therefore, even though the Doha Declaration and the 
Decision of the Council promises to ease access to essential 
medicines for developing countries like Bhutan, in practical 
terms it will be more difficult to do so. The inability to utilize 
all the flexibilities afforded by these decisions, absence of 
strong national laws and legislations, and the fear of 
repercussion from powerful Western governments and lobbies 
pose serious threats to LDC’s efforts to safeguard public 
health. More over, there is a constant danger of powerful 
countries adding TRIPS plus provisions into any bilateral or 
regional trade negotiations, which effectively deny these very 
flexibilities.  
Recommendations 
The first and foremost action that we need to take in respect 
to TRIPS and public health is to develop national laws that 
incorporate TRIPS so as to safeguard the country’s ability to 
import and deliver high quality drugs to its people. 
Regulations and legislations should address such issues as: 
granting of compulsory license to import drugs for 
government non-commercial use without prior notification; 
import and re-export within the region; registration of generic 
drugs and proof of bio-equivalence; limiting patent holders’ 
rights of appeal; setting royalty rates; defining international 
exhaustion regimes; and above all to legally enable the EDP 
and the Ministry of Trade to resort to all the flexibilities in the 
TRIPS agreement and related texts. At the same time, laws to 
prevent the re-export of licensed generics should also be 
made and enforced in order to gain the confidence of patent 
holders. Consultation should be held between the Ministry of 
Health, the Ministry of Trade, the Foreign Ministry, the Royal 
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Court of Justice, and the relevant international organizations 
that provide technical assistance. The waiver offered by the 
2003 council meeting must be incorporated as a solution 
through urgently needed national laws.  
 
Secondly, negotiations with the Indian government through 
regional organizations, such as SAFTA (South Asian Free 
Trade Agreement), should be initiated soon in order to 
address ways to increase access to generic drugs. A regional 
approach would benefit both the manufacturer in terms of 
reaching economies of scale and the member countries as 
exemplified by the African Intellectual Property Organisation. 
The decision of the General Council in paragraph 6 also 
encourages such co-operation and specifically mentions that 
“Article 31(f) of the TRIPS Agreement shall be waived to the 
extent necessary to enable a pharmaceutical product 
produced or imported under a compulsory license in that 
Member to be exported to the markets of those other 
developing or least developed country parties to the regional 
trade agreement that share the health problem in question.” 
Another mechanism that could be employed is to have a 
centralised pooled system of purchasing essential drugs. 
Pooled procurement, like the Eastern Caribbean Drug 
Service20 helps member countries to purchase drugs from a 
single manufacturer and because the bulk ordered is large, 
helps to negotiate prices and bring them down to affordable 
rates.  
 
LDC’s do not have to comply with TRIPS until 2016, and so 
Bhutan should take full advantage of the flexibilities accorded 
and in the meantime develop a pool of professionals from the 
different departments to address all the issues of TRIPS. For 
the Ministry of Health and especially the procurement 
division of the EDP, it is important that key personnel are 
trained to address these issues nationally and internationally 
                                              
20 Rouselle, M.F. and Burnett, F. “Cost containment through 
pharmaceutical procurement: A Caribbean case study,” International 
Journal of Health Planning and Management, 11 (2): 135-57. 
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so that uncertainties about patent status do not create a 
barrier. They should also ensure that appropriate policies on 
selection, purchase, appropriate taxes and prescribing 
practices are drawn up so that these factors do not feature in 
the rise of drug prices.21  
 
Bhutan should continue to push for simpler and faster 
procedures to benefit from compulsory licenses, differential 
pricing and the waiver of article 31 (f). With other partners 
Bhutan should urge the WTO to explore new ways to benefit 
poorer countries, such as equity pricing,22 automatic 
licensing and fixed royalties for patented drugs.23 It should 
negotiate with India on parallel import mechanisms and also 
on immediate export with a notification from Bhutan, without 
the cumbersome procedure of getting a compulsory license in 
India.24  
Summary 
Bhutan has an effective EDP with more than 90% of its 
people having access to high quality medicines, mainly 
generics imported from India. With India’s new patent laws, 
the sustainability of the EDP and free health care policy is 
threatened. Without a domestic pharmaceutical industry, a 
compulsory license is unlikely to benefit Bhutan and we 
should rely instead on the waiver issued by the council in 
2003. It is important that Bhutan enact its own national laws 
to safeguard affordability and access to quality drugs and 
explore all the flexibilities accorded in the Doha Declaration. 
                                              
21 Henry, D and Lexchin, J (2002). “The pharmaceutical industry as 
a medicines provider,” The Lancet, 360: 1590-95. 
22 Chaudhuri, S., Goldberg, P.K., and Jia, P. (2003). “The effect of 
extending intellectual property rights protection to developing 
countries: A case study of the Indian pharmaceutical marke,” 
National Bureau of Economic Research, working paper 10159, 
Cambridge. 
23 Chaterjee, P. (2005). “India’s new patent may still hurt generic 
drug supplies,” The lancet , 365: 1378 
24 Ahmed, K. (2005). “India’s new patent bill threatens generic 
industry,” The lancet, 5: 265. 
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It should also build a strong technical professional team to 
address these issues nationally and internationally. It is 
important to forge ties with its neighbours within the region 
to set up mechanisms to protect the fundamental right of its 
citizens to quality health care. It must ensure that its citizens 
have access to quality and effective drugs at a cost which the 
country can afford. In this highly globalised and unequal 
world, this will only be possible through its own political will. 
